Merck discontinues some cancer drug development with China`s Sichuan Kelun
Merck & Co. is broadening its pipeline of experimental cancer medicines, announcing Thursday a licensing agreement with China’s Kelun-Biotech that will give it rights to seven early-stage treatments known as antibody-drug conjugates.
CHENGDU, China, July 26, 2022 (GLOBE NEWSWIRE) -- Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd), a clinical-stage biotech company focused on biologic and small molecule discovery and development, announced today that it has entered into a collaboration and exclusive license agreement with MSD (the tradename of Merck & Co., Inc Rahway NJ USA), to develop an investigational antibody drug conjugate (ADC) for the treatment of solid tumors.
A166 is an antibody-drug conjugate (ADC) composed of an anti-HER2 antibody conjugated to Duostatin-5, a novel anti-microtubule Auristatin derivative, via a proprietary stable covalent linker.The ASCO...
In a deal potentially worth more than $1.4 billion, Sichuan Kelun Pharmaceutical Co. Ltd. has out-licensed a large molecule drug in cancer to Merck & Co. Inc. for development and commercialization outside mainland China, Hong Kong, Macao, and Taiwan.
A major Chinese pharmaceutical enterprise has established a plant in the city of Almaty in Kazakhstan. The company says the plant will provid locals with cheaper and better medicine in the future.
Chinese pharmaceutical firms recall ginkgo biloba products